Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription
Posted March 27, 2008
CT scanning to detect early lung cancers? Flawed due to ethical concerns
Analysis of: Cigarette Company Paid for Lung Cancer Study | www.nytimes.com
Author: GLG Member Program Contributor
Support from a cigarette manufacturer raises questions as to the conclusions from this study which says early detection by repetitive CT's can improve cancer cure rates by early detection. (making smoking safer?)
Posted March 25, 2008
Overuse of Lupron & Zoladex in "early" Prostate Carcinoma?
Analysis of: Prostate-Cancer Treatment Questioned | online.wsj.com
Author: GLG Member Program Contributor
Hormone blocking therapy is added to radiation, unnecessarily, in early prostate cancer patients. The result in early stage patients is unnecessary side effects and reduced quality of life. Go figure.
Posted March 25, 2008
Confirmation Trial is Needed
Analysis of: Vermillion Announces Positive Results From Clinical Trial of Ovarian Tumor Triage Test; Study Meets Primary Endpoints | www.pipelinereview.com
Author: GLG Member Program Contributor
Early detection of ovarian cancer is of paramount importance
Posted March 24, 2008
OK, now that we know why how can we prevent the reactions to increase utilization of BMS & Imclone's Erbitux?
Analysis of: Researchers Find Cause of Severe Allergic Reaction to Cancer Drug | pharmalive.com
Author: GLG Member Program Contributor
Antibodies have been identified that explain allergic reactions that can terminate it's use in individuals who "react."
Posted March 24, 2008
Sure, and let's buy them all a pony, too!
Analysis of: Vaccinating Boys for Girls’ Sake? | www.nytimes.com
Author: GLG Member Program Contributor
Everyone who thinks that the FDA is going to license a vaccine as costly as Gardasil for boys is insane (sorry if I'm being too subtle). Girls get cervical cancer; the rates of penile and anal cancers from HPV is minuscule in comparison. The cost of Gardasil for girls alone is going to strain a...
Posted March 24, 2008
Sounds impressive. Mechanism key to barrier to competition
Analysis of: MediGene Achieves Excellent Efficacy Data of EndoTAG (TM) 1 in Clinical Phase II Trial in Pancreatic Carcinoma | www.pipelinereview.com
Author: GLG Member Program Contributor
Sounds impressive. Large trial. Randomized. Dose response implied. Would like to know the evidence for a vascular mechanism.  The mechanism will be important if there is to be a barrier to competition from other formulations of paclitaxel.
Posted March 24, 2008
Piramed, GDC-0941. PI3K inhibition by GDC-941 as a promising tool to hamper a crucial tumorigenic signaling
Analysis of: Piramed Announces Progress in its Collaboration with Genentech, Inc. (DNA) to Develop a New Class of Anti-cancer Drugs | www.pipelinereview.com
Author: GLG Member Program Contributor
The PI3K/AKT/mTor signaling  has been demonstrated to be crucial in several human tumours.   Our group demonstrated that this signaling plays a pivotal role both in the  development and progression of  some thoracic malignancies such as Malignant Mesothelioma   Our...
Posted March 24, 2008
Why in pancreatic cancer???
Analysis of: MediGene Achieves Excellent Efficacy Data of EndoTAG (TM) 1 in Clinical Phase II Trial in Pancreatic Carcinoma | www.pipelinereview.com
Author: GLG Member Program Contributor
All major clinical trials in  patients with pancreatic cancer have generated questionable actual benefit
Posted March 24, 2008
Is the cost of new agents validation justifies the potential high cost in the clinical practice?
Analysis of: Piramed Announces Progress in its Collaboration with Genentech, Inc. (DNA) to Develop a New Class of Anti-cancer Drugs | www.pipelinereview.com
Author: GLG Member Program Contributor
The high cost of all the new agents is a major problem, especially in developing countries
Posted March 24, 2008
The role of immune system in the era of biological anti-cancer agents
Analysis of: Researchers Find Cause of Severe Allergic Reaction to Cancer Drug | pharmalive.com
Author: GLG Member Program Contributor
The role of immune system remains important and shouhd never neglected even with all these new molecules
Previous Page : 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Next201 to 210 of 782

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T05:45:18.353